Technology Goes Overseas, Stronger Together
There's more good news from Nanjing.
A few days ago, Nanjing-based pharmaceutical company Syngenta Pharmaceuticals announced that it had entered into an exclusive license and cooperation agreement with Boehringer Ingelheim of Germany, a leading global pharmaceutical company,...The two companies will co-develop SIM0709, a TL1A/IL-23p19 bispecific antibody developed by Centrum Pharmaceuticals, for the treatment of inflammatory bowel disease.
An innovative drug that is still in the preclinical stage, because of its innovative therapeutic approach and potentially huge market.Up to 1.058 billion euros (about 8 billion yuan) in overseas interests.
A Chinese originator not yet on the market
Why can it attract international giants to spend huge amounts of money to introduce it?
SIM0709 is not an ordinary antibody drug, but a bispecific antibody that can target both TL1A and IL-23p19. In the field of inflammatory bowel disease, existing therapies mostly target a single pathway, while the development of the disease often involves multiple signaling pathways "crosstalk".SIM0709 is equivalent to a "double warhead missile", synchronously blocking two core inflammatory pathways, preclinical studies have shown that its effect is better than the combination of two single-target drugs, to achieve the synergistic effect of "1+1＞2".
Inflammatory bowel disease (IBD) affects more than 3 million people globally and its incidence continues to rise in developing countries. The disease requires lifelong treatment, but existing drugs have limited effect on many patients, and there is a large unmet clinical need for recurring disease and complications, which represents a huge market opportunity for the future.
"Through this collaboration, Centrum Pharmaceuticals and Boehringer Ingelheim will work together to advance the development of innovative therapies with a view to redefining effective treatments and improving the treatment and quality of life for patients worldwide."Zhou Gaobo, chief investment officer of Centaur Pharmaceuticals, said.
The research and development of innovative drugs is a systematic project, which needs to go through different phases such as preclinical, clinical phase I, phase II, phase III, etc., and each of these phases requires huge investment in research and development costs. Industry analysts analyze, "Currently, with the development of the domestic biopharmaceutical industry, many international pharmaceutical giants attach great importance to the research and development capabilities of Chinese pharmaceutical companies, and will purchase overseas rights and interests in the form of early involvement in the research and development of new drugs, with a view to seizing the first opportunity in the process of new drugs on the market."
The signing of this agreement means that Boehringer Ingelheim Germany is very optimistic about the prospect of SIM0709's research and development before coming to us.The two sides will jointly invest human and financial resources to promote the development of new drugs more efficiently.
Zhou Gaobo said."SIM0709 was developed from Centrum Pharmaceuticals' multi-antibody technology platform and has the potential to be 'first of its kind' in the field of inflammatory bowel disease treatment."
Carine, Head of Global Immunology and Respiratory Diseases Research and Development at Boehringer Ingelheim, said, "Inflammatory bowel disease affects a huge patient population, many of whom continue to progress and experience serious complications despite the use of existing anti-inflammatory therapies. We are pleased to join forces with Centrum Pharmaceuticals to accelerate the development of this potentially innovative therapy that could change the lives of patients with inflammatory bowel disease."
Behind a single authorization.It's technical hard power.
As a matter of fact, this is not the first time that Centrum Pharmaceuticals has gone overseas with its technology; previously, theThe company has entered into licensing cooperation with a group of pharmaceutical giants such as AbbVie (USA), Ipsen (France) and NextCure (USA).
As of today.CCTV has five early-stage research projects of self-developed innovative drugs that have achieved overseas technology licensing, and the total potential transaction amount has exceeded US$4.6 billion in total.The funds received will be used to continue R&D investment, advance more innovative projects and accelerate clinical studies in China and overseas.
Biomedicine as an important part of the city's "1026" industrial system, the momentum of development has been strong in recent years, and the story of "Nanjing's innovation, the global order" is also constantly staged:
- Velizipor and Dianthus Therapeutics enter into an exclusive global partnership in a deal totaling up to $1 billion;
- PharmaJet Anacott and Neurocrine Biosciences enter into a program partnership with a total potential value of $881.5 million ......
These innovative drugs that have completed the "technology realization" are actually the first of their kind and the best of their kind.
From "0 to 1" of the original innovation is a very high investment, risky "adventure", how to survive the test of 3 "10"? In the field of biomedicine in Nanjing, there is never a lack of support.
In recent years, Nanjing has introduced a package of policy documents such as "Nanjing to promote the high-quality development of the biomedical industry a number of policies and measures", covering the whole chain of talent research, industrial ecology, overseas expansion.
2025
Nanjing establishes a total of 2 billion yuan
Zijin Biomedical Fund
Jiangbei New Area gathers 14 special funds
Total size exceeds $5.7 billion
Providing financial "water" for innovative projects
Just last year.
Three Class I Innovative Drugs Approved in Nanjing
Ranked among the top cities in the country
The biomedical industry for the year is expected to
Revenue to exceed $225 billion
